At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Immunogenicity & Safety Study of GSK Biologicals' 208136 Vaccine Formulated With New Measles and Rubella Working Seeds
In Brief
A Phase 2 clinical trial evaluating Priorix-Tetra (combined measles-mumps-rubella-varicella vaccine) and GSK Biologicals' 208136, new formulation for Measles and 3 related conditions. Completed, enrolled 501 participants across 6 sites in 2 countries.
Detailed Summary
This study is undertaken to generate clinical data on GSK Biologicals' combined measles-mumps-rubella-varicella vaccine manufactured with measles and rubella obtained from newly established working seed viruses which are one passage further than the current working seed viruses. The measles-mumps-rubella-varicella vaccine manufactured with the current working seed viruses will serve as comparator. A seed lot system is a system according to which successive batches of a vaccine are derived from the same master seed virus. For routine production, a working seed lot is prepared from the master seed virus.
Study Details
Timeline
Interventions
Vaccine will be administered subcutaneously in the left upper arm (deltoid region)
Vaccine will be administered subcutaneously in the left upper arm (deltoid region)